Establishment Labs (NASDAQ:ESTA – Get Free Report) is projected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Establishment Labs to post earnings of ($0.2568) per share and revenue of $66.81 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.
Establishment Labs (NASDAQ:ESTA – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The company’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.57) earnings per share. On average, analysts expect Establishment Labs to post ($1.08) EPS for the current fiscal year and ($0.01) EPS for the next fiscal year.
Establishment Labs Trading Up 3.1%
NASDAQ ESTA opened at $65.78 on Tuesday. Establishment Labs has a 1-year low of $47.00 and a 1-year high of $97.59. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The stock’s 50 day simple moving average is $67.70 and its 200-day simple moving average is $72.40.
Analyst Ratings Changes
A number of research firms recently weighed in on ESTA. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, September 21st. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective on the stock in a report on Thursday, August 13th. BTIG Research reissued a “buy” rating and set a $103.00 target price on shares of Establishment Labs in a research note on Tuesday, September 1st. TD Cowen reduced their target price on Establishment Labs from $117.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research note on Thursday, August 6th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $96.11.
Check Out Our Latest Analysis on ESTA
Establishment Labs Company Profile
Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.
Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.
Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.
Read More
- Five stocks we like better than Establishment Labs
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
